Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting.

CONCLUSION: Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine. PMID: 31701170 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research

Related Links:

Abstract Suppression of TP53 function is nearly ubiquitous in human cancers, and a significant fraction of cancers have mutations in the TP53 gene itself. Therefore, the wild-type TP53 gene has become an important target gene for transformation research of cancer gene therapy. In 2003, the first anti-tumor gene therapy drug rAd-p53 (recombinant human p53 adenovirus), trade name Gendicine™, was approved by the China Food and Drug Administration (CFDA) for treatment of head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy. The recombinant human TP53 gene is delivered into cancer cells ...
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research
Objective: Despite the standard treatment of head and neck squamous cell carcinoma (HNSCC) with chemotherapy, radiotherapy, and/or surgery, survival rates are still low. In recent years, a greater understanding of cellular interaction within the tumor microenvironment has allowed for the identification of (1) immune evasion that promotes the development and progression of tumors and (2) the application of immunotherapy. The aim of this study is to summarize the main findings of the research on the expression of immune- checkpoint inhibition molecules in HNSCC cases and possible immunotherapeutic use.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190481 Source Type: research
Abstract Treatment of locoregionally advanced head and neck squamous cell carcinoma involves a multidisciplinary approach that combines surgery, radiotherapy, and systemic therapy. These curative strategies are associated with significant acute and long-term toxicities. With the emergence of human papillomavirus (HPV) as an etiologic factor associated primarily with oropharyngeal squamous cell carcinoma, higher cure rates juxtaposed with substantial treatment-related morbidity and mortality has led to interest in de-escalated therapeutic strategies, with the goal of optimizing oncologic outcomes while reducing tre...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Abstract Head and neck squamous cell carcinoma (HNSCC) is a deadly disease which in many cases is managed with a combination of radiation and chemotherapy. Unfortunately, the ability to monitor treatment response in real time is limited. Thus, truly individualized therapy remains an unrealized goal. We have previously investigated the possibility of combining advanced imaging using magnetic resonance imaging (MRI) combined with the analysis of circulating tumor cells to classify response in HNSCC as part of a prospective trial (PREDICT-HN). An adaption of the methodology from that trial is described herein in hope...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
Oral squamous cell carcinoma (OSCC), a form of head and neck squamous cell carcinoma (HNSCC) has a poor 5-year survival rate. OSCC patients are often treated with cisplatin but resistance to chemotherapy is of...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
ne Noda Nakagawa Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received S1, an oral flu...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This cohort study uses data from the National Cancer Database to assess whether adding chemotherapy to adjuvant radiation therapy is associated with improved survival among patients with human papillomavirus –negative head and neck squamous cell carcinoma with extranodal extension from a single lymph node smaller than 3 cm.
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research
Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma. Oncol Rep. 2020 Sep;44(3):863-872 Authors: Tsuchihashi H, Naruse T, Yanamoto S, Okuyama K, Furukawa K, Omori K, Umeda M Abstract High expression of the 110 kDa catalytic subunit of the class IA PI3K (PI3Kp110α) may play an important role in cetuximab resistance exhibited by both colorectal cancer and head and neck squamous cell carcinoma. Therefore, the present study aimed to examine the association between the expression of proteins in the PI3Kp110α pathw...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
amada In the treatment of advanced head and neck squamous cell carcinoma (HNSCC), including oral SCC, radiotherapy is a commonly performed therapeutic modality. The combined use of radiotherapy with chemotherapy improves therapeutic effects, but it also increases adverse events. Ceramide, a central molecule in sphingolipid metabolism and signaling pathways, mediates antiproliferative responses, and its level increases in response to radiotherapy and chemotherapy. However, when ceramide is metabolized, prosurvival factors, such as sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P), and glucosylceramide, are produ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: The interval between surgery and RT did not show influence on locoregional control rates. However, doses150 days were associated with lower locoregional control rates.
Source: Clinics - Category: General Medicine Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Conferences | Docetaxel | ENT & OMF | Erbitux | HNSCC | Skin Cancer | Squamous Cell Carcinoma | Study | Taxotere | Toxicology